Search results for "VACCINE"

showing 10 items of 801 documents

mRNA: A Versatile Molecule for Cancer Vaccines

2016

mRNA vaccines are finally ready to assume their rightful place at the forefront of nucleic acid- based vaccines. Major achievements within the last two decades have turned this highly versatile molecule into a safe and very attractive pharmaceutical platform that combines many positive attributes able to address a broad range of diseases, including cancer. The simplicity of mRNA vaccines greatly reduces complications generally associated with the production of biological vaccines. Intrinsic costimulatory and inflammatory triggers in addition to the provision of the antigenic information makes mRNA an all- in-one molecule that does not need additional adjuvants and that does not pose the ris…

0301 basic medicineVaccinesMoleculeImmunotherapy ActiveCancerGeneral MedicineBiologymedicine.diseaseBioinformaticsmRNA:Cancer VaccinesVersatileCancer treatment03 medical and health sciences030104 developmental biologyNeoplasmsmedicineHumansRNA MessengerCancerCurrent Issues in Molecular Biology
researchProduct

Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma

2017

Antonio Miguel,1 Luis Sendra,1 Verónica Noé,2 Carles J Ciudad,2 Francisco Dasí,3,4 David Hervas,5 María José Herrero,1,6 Salvador F Aliño17 1Department of Pharmacology, Faculty of Medicine, University of Valencia, 2Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of Barcelona, 3Research University Hospital of Valencia, INCLIVA Health Research Institute, 4Department of Physiology, Faculty of Medicine, University of Valencia Foundation, 5Biostatistics Unit, 6Pharmacogenetics Unit, Instituto de Investigación Sanitaria La Fe (IIS La Fe), 7Clinical Pharmacology Unit, ACM Hospital Univers…

0301 basic medicineantisense oligonucleotidemedicine.medical_treatmentCellImmunoteràpiaIpilimumabchemical and pharmacologic phenomenaImmunotheraphyVacuneslcsh:RC254-282OncoTargets and Therapy03 medical and health sciencesgene silencingCancer immunotherapymedicineGene silencingPharmacology (medical)IL-2 receptorCàncerOriginal ResearchTumorsCancerVaccinescancer immunotherapybiologybusiness.industryFOXP3hemic and immune systemslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensVaccinationTreg030104 developmental biologymedicine.anatomical_structureantitumor vaccineOncologybiology.proteinCancer researchAntibodybusinessmedicine.drugOncoTargets and Therapy
researchProduct

Protein corona–mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses

2018

Background Nanoparticle (NP)–based vaccines are attractive immunotherapy tools because of their capability to codeliver antigen and adjuvant to antigen-presenting cells. Their cellular distribution and serum protein interaction ("protein corona") after systemic administration and their effect on the functional properties of NPs is poorly understood. Objectives We analyzed the relevance of the protein corona on cell type–selective uptake of dextran-coated NPs and determined the outcome of vaccination with NPs that codeliver antigen and adjuvant in disease models of allergy. Methods The role of protein corona constituents for cellular binding/uptake of dextran-coated ferrous nanoparticles (DE…

0301 basic medicineendocrine systemOvalbuminCpG OligodeoxynucleotideT-Lymphocytesmedicine.medical_treatmentImmunologyMice Transgenic02 engineering and technologyComplement factor IComplement receptor03 medical and health sciencesImmune systemAntigenLectinsHypersensitivitymedicineAnimalsImmunology and AllergyFerrous CompoundsAntigensAnaphylaxisB-LymphocytesDrug CarriersMice Inbred BALB CVaccinesChemistryDextransImmunotherapyrespiratory system021001 nanoscience & nanotechnologyComplement systemMice Inbred C57BL030104 developmental biologyOligodeoxyribonucleotidesImmunologyNanoparticlesFemaleProtein Corona0210 nano-technologyAdjuvantJournal of Allergy and Clinical Immunology
researchProduct

Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model.

2017

Coxsackie B viruses are among the most common enteroviruses, causing a wide range of diseases. Recent studies have also suggested that they may contribute to the development of type 1 diabetes. Vaccination would provide an effective way to prevent CVB infections, and the objective of this study was to develop an efficient vaccine production protocol for the generation of novel CVB vaccines. Various steps in the production of a formalin-inactivated Coxsackievirus B1 (CVB1) vaccine were optimized including the Multiplicity Of Infection (MOI) used for virus amplification, virus cultivation time, type of cell growth medium, virus purification method and formulation of the purified virus. Safety…

0301 basic medicineformalin inactivationviruksetvirusesDrug Evaluation PreclinicalPolysorbatesmedicine.disease_causeAntibodies ViralMice0302 clinical medicineMultiplicity of infectionImmunogenicity VaccinevaccineChlorocebus aethiops030212 general & internal medicineImmunogenicityVaccinationVaccinationInfectious Diseasescoxsackievirus B1Molecular MedicineFemaleUltracentrifugeVirus CultivationCoxsackievirus InfectionsBiologyCoxsackievirusta3111VirusMicrobiology03 medical and health sciencesFormaldehydemedicineAnimalsCVB1Vero CellscoxsackievirusGeneral VeterinaryGeneral Immunology and Microbiologyrokotteetta1182Public Health Environmental and Occupational HealthViral Vaccinesbiology.organism_classificationVirologyAntibodies NeutralizingVirus CultivationEnterovirus A HumanDisease Models Animal030104 developmental biologyVaccines Inactivatedvirus purificationEnterovirusVaccine
researchProduct

Immunization Status against Measles of Health-Care Workers Operating at Three Sicilian University Hospitals: An Observational Study

2019

Measles is a highly contagious vaccine-preventable disease (VPD) that also commonly affects health-care workers (HCWs). Measles immunization of HCWs was strongly recommended by international health authorities, in order to limit the spreading of the illness to susceptible patients and colleagues. An observational study, evaluating the immunization and vaccination status against measles of HCWs working at three Sicilian university hospitals, was conducted. All subjects not completely immune (vaccinated with only one dose in their lifetime), not immune (not vaccinated or not naturally immunized), and with an unknown immunization status were considered not immunized. Among HCWs operating in th…

0301 basic medicinehealth care facilities manpower and servicesanimal diseases030106 microbiologyImmunologyeducationlcsh:Medicinechemical and pharmacologic phenomenaDiseaseSettore MED/42 - Igiene Generale E ApplicataMeaslesArticle03 medical and health sciences0302 clinical medicineEnvironmental healthDrug DiscoveryHealth careHealth-care personnel Vaccine hesitancy Vaccine-preventable diseasemedicinePharmacology (medical)vaccine-preventable disease030212 general & internal medicinePharmacologybusiness.industrylcsh:RInternational healthhealth-care personnelbiochemical phenomena metabolism and nutritionmedicine.diseaseUniversity hospitalVaccinationInfectious DiseasesImmunizationHealth-care personnel; Vaccine hesitancy; Vaccine-preventable diseasebacteriavaccine hesitancyObservational studybusinessVaccines
researchProduct

The Protein Corona as a Confounding Variable of Nanoparticle-Mediated Targeted Vaccine Delivery

2018

Nanocarriers (NC) are very promising tools for cancer immunotherapy. Whereas conventional vaccines are based on the administration of an antigen and an adjuvant in an independent fashion, nanovaccines can facilitate cell-specific co-delivery of antigen and adjuvant. Furthermore, nanovaccines can be decorated on their surface with molecules that facilitate target-specific antigen delivery to certain antigen-presenting cell types or tumor cells. However, the target cell-specific uptake of nanovaccines is highly dependent on the modifications of the nanocarrier itself. One of these is the formation of a protein corona around NC after in vivo administration, which may potently affect cell-speci…

0301 basic medicinelcsh:Immunologic diseases. AllergyMini Reviewmedicine.medical_treatmentImmunologyCellcell-specific targetingProtein Corona02 engineering and technology03 medical and health sciencesprotein coronaAntigenCancer immunotherapyIn vivoNeoplasmsmedicineHumansImmunology and AllergyReceptors ImmunologicnanocarriersChemistryImmunotherapy021001 nanoscience & nanotechnologyBody FluidsTreatment Outcome030104 developmental biologymedicine.anatomical_structureCancer researchNanoparticlesimmunotherapyNanocarriers0210 nano-technologylcsh:RC581-607Adjuvantcancer vaccinesProtein BindingFrontiers in Immunology
researchProduct

HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory

2019

ABSTRACT HPV16 infections are associated with a variety of cancers and there is compelling evidence that the transforming activity of HPV16 critically depends on the expression of the viral oncoproteins E6 and E7. Therapeutic cancer vaccines capable of generating durable and specific immunity against these HPV16 antigens hold great promise to achieve long-term disease control. Here we show in mice that HPV16 E7 RNA-LPX, an intravenously administered cancer vaccine based on immuno-pharmacologically optimized antigen-encoding mRNA, efficiently primes and expands antigen-specific effector and memory CD8+ T cells. HPV-positive TC-1 and C3 tumors of immunized mice are heavily infiltrated with ac…

0301 basic medicinelcsh:Immunologic diseases. AllergyT cellImmunologyhpv16-positive malignancieslcsh:RC254-282t cell memoryhpv 16 rna-lpx03 medical and health sciences0302 clinical medicineImmune systemAntigenImmunology and AllergyCytotoxic T cellMedicineOriginal Researchbusiness.industryCancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologymedicine.anatomical_structureOncologyImmunization030220 oncology & carcinogenesisCancer researchCancer vaccinebusinesscancer vaccinelcsh:RC581-607CD8e7OncoImmunology
researchProduct

Harnessing Unconventional T Cells for Immunotherapy of Tuberculosis

2020

Even if the incidence of tuberculosis (TB) has been decreasing over the last years, the number of patients with TB is increasing worldwide. The emergence of multidrug-resistant and extensively drug-resistant TB is making control of TB more difficult. Mycobacterium bovis bacillus Calmette–Guérin vaccine fails to prevent pulmonary TB in adults, and there is an urgent need for a vaccine that is also effective in patients with human immunodeficiency virus (HIV) coinfection. Therefore, TB control may benefit on novel therapeutic options beyond antimicrobial treatment. Host-directed immunotherapies could offer therapeutic strategies for patients with drug-resistant TB or with HIV and TB coinfecti…

0301 basic medicinelcsh:Immunologic diseases. AllergyTuberculosismedicine.medical_treatmentT cellImmunologyCD1HIV InfectionsMajor histocompatibility complexMucosal-Associated Invariant T Cellshost-directed therapy03 medical and health sciences0302 clinical medicineMHC class ImedicineImmunology and AllergyHumansTuberculosis Pulmonarybiologybusiness.industryImmunotherapyMycobacterium tuberculosisDonor Lymphocytesmedicine.diseaseAdoptive Transfer030104 developmental biologymedicine.anatomical_structuretuberculosisImmunologybiology.proteinCoinfectionBCG VaccineHIV-1cytotoxicityT cell receptorbusinesslcsh:RC581-607unconventional T cells030215 immunologyFrontiers in Immunology
researchProduct

Localized Interleukin-12 for Cancer Immunotherapy

2020

Interleukin-12 (IL-12) is a potent, pro-inflammatory type 1 cytokine that has long been studied as a potential immunotherapy for cancer. Unfortunately, IL-12's remarkable antitumor efficacy in preclinical models has yet to be replicated in humans. Early clinical trials in the mid-1990's showed that systemic delivery of IL-12 incurred dose-limiting toxicities. Nevertheless, IL-12's pleiotropic activity, i.e., its ability to engage multiple effector mechanisms and reverse tumor-induced immunosuppression, continues to entice cancer researchers. The development of strategies which maximize IL-12 delivery to the tumor microenvironment while minimizing systemic exposure are of increasing interest…

0301 basic medicinelcsh:Immunologic diseases. Allergymedicine.medical_treatmentDrug CompoundingImmunologyGenetic Vectorsinterleukin-12 (IL-12)Antineoplastic AgentsReviewBioinformatics03 medical and health sciences0302 clinical medicineCancer immunotherapyNeoplasmsintratumoral administrationTumor MicroenvironmentImmunology and AllergyMedicineAnimalsHumansTumor microenvironmentDrug Carrierscancer immunotherapyAntitumor immunitybusiness.industryGene Transfer TechniquesCancerImmunotherapyGenetic Therapymedicine.diseaseInterleukin-12Clinical trialcytokine delivery system030104 developmental biologyTreatment OutcomeInterleukin 12Cancer vaccineImmunotherapybusinesslcsh:RC581-607cancer vaccinelocalized delivery030215 immunologyFrontiers in Immunology
researchProduct

mRNA-Based Vaccines

2021

Increases in the world’s population and population density promote the spread of emerging pathogens. Vaccines are the most cost-effective means of preventing this spread. Traditional methods used to identify and produce new vaccines are not adequate, in most instances, to ensure global protection. New technologies are urgently needed to expedite large scale vaccine development. mRNA-based vaccines promise to meet this need. mRNA-based vaccines exhibit a number of potential advantages relative to conventional vaccines, namely they (1) involve neither infectious elements nor a risk of stable integration into the host cell genome; (2) generate humoral and cell-mediated immunity; (3) are well-t…

0301 basic medicinemRNAinfectious diseaseImmunologyPopulationlcsh:MedicineComputational biologyReviewBiologylipid nanoparticles03 medical and health sciences0302 clinical medicineImmunityDrug DiscoverycancerPharmacology (medical)educationPharmacologyeducation.field_of_studylcsh:Rvaccine constructsdelivery systems030104 developmental biologyInfectious DiseasesInfectious disease (medical specialty)030220 oncology & carcinogenesisHealthy individualsVaccines
researchProduct